LinkedInXFacebook
Subscribe
Orthopedics This Week
  • My Feed
  • |Posts
  • |Events
  • |MSK Innovations
  • |Power Rankings
  • |Masterclasses
  • |Technology Awards
  • Press Releases
  • |Advertising
  • |Job Board
  • Spine
  • ◆Joints
  • ◆Upper Extremities
  • ◆Foot & Ankle
  • ◆Sports Medicine
  • ◆Pain Mgmt
  • ◆Trauma
  • ◆Biologics
  • ◆Technology
  • ◆People
  • ◆Company News
  • ◆Legal & Regulatory
Home/Legal & Regulatory and Reimbursement/New Threat to 1099 Distributors Emerges in Lawsuit
Legal & Regulatory and Reimbursement

New Threat to 1099 Distributors Emerges in Lawsuit

August 20, 2024 2 min read Premium comments

Advertisement

New Threat to 1099 Distributors Emerges in Lawsuit
Source: Gencraft.com and Kim DelMonico
#zimmerbiomet#antikickbackstatute#falseclaimsact#advamed#advancedmedicaltechnologyassociation

A lawsuit alleging that Zimmer’s independent contractor (aka:1099s) compensation structure violates the Anti-Kickback Statutes and False Claims Act has survived Zimmer’s motion to dismiss and could actually go to trial.

Zimmer’s motion to dismiss this potential threat to the system of 1099 independent contractors who sell and distribute medical devices was based on two important arguments:

  1. The whistleblower (the Relator’s) complaint failed to state a claim for violation of the Anti-Kickback Statute, and
  2. The Relator’s complaint is precluded by the public disclosure bar.

Judge Patti B. Saris of the United States District Court for the District of Massachusetts was not persuaded. The trial is on.

Interestingly, the U.S. Attorney declined to intervene, even though it was a whistleblower case but it did submit supplemental authority to the Court which identified case law where commission-based independent contractors were held to violate the Anti-Kickback Statute.

Medical device trade group, AdvaMed (The Advanced Medical Technology Association) filed an amicus brief in support of Zimmer’s motion to dismiss. AdvaMed argued that the practice of “employing independent sales agents to market and facilitate the sale of its medical devices” is a “practice that is widespread within, and vital to, the medical device industry and the patients it serves.”

AdvaMed went on to say that this entire case is a “fundamental misunderstanding of the Anti-Kickback Statute, as well as the relevant guidance from the United States Department of Health and Human Services Office of Inspector General.”

Judge Saris, ruled that the Relator’s allegations were plausible “given the breadth of the Anti-Kickback Statute and the characteristics of the independent contractor arrangement alleged here” and therefore constituted a claim for violating the Anti-Kickback Statute.

Judge Saris agreed with Zimmer’s second argument and found that “the essential elements of Relator’s complaint were publicly disclosed, thus triggering the public disclosure bar.” But, the Relator’s counter argument overcame Zimmer Biomet’s logic thanks to an “escape hatch” which demonstrated that the Relator “has knowledge that is independent from public disclosures.”

Advertisement

The lawsuit was filed by a former employee of Zimmer. The former employee worked for about ten years as a senior sales associate supporting sales of orthopedic medical devices.

The Relator claims that the violations began in June 2015 when Zimmer Holdings, Inc. acquired Biomet, Inc. After the acquisition, the Relator claims that the merged company adopted the independent contractor model for all of its sales reps.

This case could have implications for medical device companies relying on sales-based commissions for their independent contractors. OTW will monitor the litigation.

React:

Discussion

14
DS
Dr. Sarah MitchellOrthopedic Surgeon · Mayo Clinic

This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?

8
JT
James Thornton, MDSpine Fellow · HSS

Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.

5
RP
R. PatelSports Medicine · Stanford

We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.

Join the conversation

Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.

Subscribe

Get Full Access

Read every OTW article and join member discussions for $24.99/month.

Get Full Access

Advertisement

Advertisement

Advertisement

Orthopedics This Week

The most trusted source in orthopedic industry news since 2005. Covering spine, joints, trauma, biologics, and the business of orthopedics.

A publication of RRY Publications, LLC

LinkedInXFacebook

Categories

  • Spine
  • Joints
  • Upper Extremities
  • Foot & Ankle
  • Sports Medicine
  • Pain Mgmt
  • Trauma
  • Biologics
  • Technology
  • People
  • Company News
  • Legal & Regulatory

Resources

  • Subscribe
  • Community Posts
  • Job Board
  • Press Release Opportunities
  • Power Rankings
  • About OTW
  • Advertise
  • Contact Us

Get Full Access

Unlimited articles, community posts, and Power Rankings.

Get Full Access

Plans start at $24.99/mo · Annual saves 20%

© 2026 Orthopedics This Week · RRY Publications, LLC

Privacy PolicyTerms of ServiceCookie Policy